Use of Citalopram in Pervasive Developmental Disorders
The DOI matches its Crossref record.
Abstract
This study assessed the effectiveness and tolerability of the selective serotonin reuptake inhibitor citalopram in the treatment of patients with pervasive developmental disorders (PDDs). The medical charts of 15 children and adolescents (aged 6-16 yr) with Asperger syndrome, autism, or PDD not otherwise specified treated with citalopram were retrospectively reviewed. The final dose of citalopram was 16.9 +/- 12.1 mg/day with a treatment duration of 218.8 +/- 167.2 days. Independent ratings of the Clinical Global Impression (CGI) Severity and Improvement scales allowed comparison between baseline and PDD symptoms at the last visit. Eleven adolescents (73%) exhibited significant improvement in PDD, anxiety, or mood CGI score (z = 2.95; p =.003). Anxiety symptoms associated with PDDs improved significantly in 66% of patients (z = 2.83, p =.005), and mood symptoms improved significantly in 47% of patients (z = 2.78, p =.005). Mild side effects were reported by five patients (33%). These data suggest citalopram may be effective, safe, and well tolerated as part of the treatment of PDDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Marazziti, 2000, Pharmacopsychiatry, 33, 165, 10.1055/s-2000-7588 · DOI · Paper page
- Croonenberghs, 2000, Neuropsychopharmacology, 22, 275, 10.1016/S0893-133X(99)00131-1 · DOI
- McDougle, 2000, J Autism Dev Disord, 30, 427, 10.1023/A:1005551523657 · DOI · Paper page
- McDougle, 1996, Arch Gen Psychiatry, 53, 1001, 10.1001/archpsyc.1996.01830110037005 · DOI · Paper page
- Cook, 1992, J Am Acad Child Adolesc Psychiatry, 31, 739, 10.1097/00004583-199207000-00024 · DOI · Paper page
- Fatemi, 1998, J Autism Dev Disord, 28, 303, 10.1023/A:1026008602540 · DOI
- DeLong, 1998, Dev Med Child Neurol, 40, 551, 10.1111/j.1469-8749.1998.tb15414.x · DOI · Paper page
- Alcami Pertejo, 2000, Actas Esp Psiquiatr, 28, 353
- Hellings, 1996, J Clin Psychiatry, 57, 333
- McDougle, 1998, Arch Gen Psychiatry, 55, 633, 10.1001/archpsyc.55.7.633 · DOI · Paper page
- Steingard, 1997, J Child Adolesc Psychopharmacol, 7, 9, 10.1089/cap.1997.7.9 · DOI · Paper page
- Willetts, 1999, J Clin Psychopharmacol, 19, 36S, 10.1097/00004714-199910001-00004 · DOI
- Gutierrez, 2000, Pharmacotherapy, 20, 1441, 10.1592/phco.20.19.1441.34851 · DOI · Paper page
- Baumann, 1995, Int Clin Psychopharmacol, 10, 15, 10.1097/00004850-199503001-00004 · DOI
- von Moltke, 1999, Biol Psychiatry, 46, 839, 10.1016/S0006-3223(98)00353-9 · DOI
- Arnold, 2000, J Autism Dev Disord, 30, 99, 10.1023/A:1005451304303 · DOI
- Thomsen, 2001, J Am Acad Child Adolesc Psychiatry, 40, 895, 10.1097/00004583-200108000-00010 · DOI
- Bostic, 2001, J Child Adolesc Psychopharmacol, 11, 159, 10.1089/104454601750284063 · DOI
- Schaller, 2001, Med Gen Med, 3, 1, 10.1002/1521-2254(200101/02)3:1<1::AID-JGM170>3.0.CO;2-6 · doi:10.1002/1521-2254(200101/02)3:1<1::aid-jgm170>3.0.co;2-6
- Peral, 1999, J Am Acad Child Adolesc Psychiatry, 38, 1472, 10.1097/00004583-199912000-00005 · DOI
- Hollander, 2000, J Child Neurol, 15, 132, 10.1177/088307380001500214 · DOI · Paper page
- Posey, 2001, J Child Adolesc Psychopharmacol, 11, 267, 10.1089/10445460152595586 · DOI · Paper page
- Montgomery, 1994, Int Clin Psychopharmacol, 9, 35, 10.1097/00004850-199403001-00006 · DOI · Paper page
Cited by
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Anxiety in children and adolescents with autism spectrum disorders
White, S. W., Oswald, D., Ollendick, T., & Scahill, L. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.003 · Cited by 1,427
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Metadata
- Authors
- NAMEROW, L. B., THOMAS, P., BOSTIC, J. Q., PRINCE, J., & MONUTEAUX, M. C.
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2003-04
- Volume
- 24
- Issue
- 2
- Pages
- 104-108
- ISSN
- 0196-206X (ISSN-L)
- OpenAlex
- W1978189785
- Cited by
- 121
- References
- 0
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Citalopram in Pervasive Developmental Disorders. https://app.cochat.ai/papers/10.1097/00004703-200304000-00005
- The paper
- NAMEROW, L. B., THOMAS, P., BOSTIC, J. Q., PRINCE, J., & MONUTEAUX, M. C. (2003). Use of Citalopram in Pervasive Developmental Disorders. Journal of Developmental & Behavioral Pediatrics. https://doi.org/10.1097/00004703-200304000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.